Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma Post date October 12, 2022 ← Antitumor activity of T cells expressing a novel anti-FOLR1 CoStAR in a human xenograft murine solid tumor model and implications for in-human studies → ITIL-306-201: A Multicenter, First-in-Human Phase 1a/1b Study of ITIL-306, an Engineered Autologous TIL Cell Therapy Product, in Adults With Advanced Solid Tumors
Instil Bio